Observational Study of ASCVD Risks of Type 2 Diabetes in East China

Inclusion Criteria: * Type 2 diabetes * HbA1c ≥7.0% * Prior CVD cohort: age ≥50 and ≥1 of the following criteria. * Prior MI * Prior stroke or TIA * Prior coronary, carotid or peripheral arterial revascularization * N50% stenosis of coronary, carotid, or lower extremity arteries * History of symptomatic CHD documented by Positive exercise stress test or any cardiac imaging or Unstable angina with ECG changes * Asymptomatic cardiac ischemia Documented by positive nuclear imaging test, exercise test or dobutamine stress echo * Chronic heart failure NYHA class II-III * Chronic renal failure, eGFR \<60 mL/min per 1.73m2 MDRD eGFR \<60 mL/min per Cockcroft-Gault formula * No Prior CVD group: Age ≥60 y and ≥1 of the following criteria. * Microalbuminuria or proteinuria * Hypertension and left ventricular hypertrophy by ECG or imaging * Left ventricular systolic or diastolic dysfunction by imaging * Ankle-brachial index b0.9 Exclusion Criteria: * Type 1 diabetes * other type diabetes * Calcitonin ≥50 ng/L * Use of a GLP-1 receptor agonist (exenatide, liraglutide or other) or pramlintide or any DPP-4 inhibitor within the 3 months prior to screening * Use of insulin other than human NPH insulin or long-acting insulin analogue or premixed insulin within 3 months prior to screening. Shortterm use of other insulin during this period in connection with intercurrent illness is allowed, at Investigators discretion * Acute decompensation of glycemic control * An acute coronary or cerebrovascular event in the previous 14 d * Currently planned coronary, carotid, or peripheral artery revascularization * Chronic heart failure (NYHA class IV) * Current continuous renal replacement therapy * End-stage liver disease * History of solid organ transplant or awaiting solid organ transplant * Malignant neoplasm * Family or personal history of multiple endocrine neoplasia type 2 (MEN2) or familial medullary thyroid carcinoma (FMTC) * Personal history of non-familial medullary thyroid carcinoma